Cargando…
Drug therapy for hereditary cancers
Tumors arising in patients with hereditary cancer syndromes may have distinct drug sensitivity as compared to their sporadic counterparts. Breast and ovarian neoplasms from BRCA1 or BRCA2 mutation carriers are characterized by deficient homologous recombination (HR) of DNA, that makes them particula...
Autores principales: | Imyanitov, Evgeny N, Moiseyenko, Vladimir M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171323/ https://www.ncbi.nlm.nih.gov/pubmed/21819606 http://dx.doi.org/10.1186/1897-4287-9-5 |
Ejemplares similares
-
Cytotoxic and targeted therapy for hereditary cancers
por: Iyevleva, Aglaya G., et al.
Publicado: (2016) -
Systemic therapy for hereditary cancer
por: Imyanitov, Evgeny N
Publicado: (2012) -
Systemic treatment for hereditary cancers: a 2012 update
por: Imyanitov, Evgeny N, et al.
Publicado: (2013) -
Hereditary cancer syndromes
por: Imyanitov, Evgeny N, et al.
Publicado: (2023) -
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
por: Imyanitov, Evgeny N.
Publicado: (2021)